Co-management of the liver and the kidney： New prospects in the clinical management of metabolic dysfunction-associated fatty liver disease with chronic kidney disease

Qiongyue FAN; Danqin SUN; Chunsun DAI; Minghua ZHENG

doi:10.12449/JCH250905

Volume 41 Issue 9

Sep. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(9): 1744-1751

PDF( 1023 KB)

Co-management of the liver and the kidney： New prospects in the clinical management of metabolic dysfunction-associated fatty liver disease with chronic kidney disease

DOI: 10.12449/JCH250905

1.
Liver Disease Center，Department of Infectious Diseases，The First Affiliated Hospital of Wenzhou Medical University，Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province，Wenzhou，Zhejiang 325000，China
2.
Department of Nephrology，Affiliated Central Hospital of Jiangnan University，Wuxi，Jiangsu 214000，China
3.
Center for Kidney Disease，The Second Affiliated Hospital of Nanjing Medical University，Nanjing 210003，China

Research funding:

National Key R D Program of China (2023YFA1800801);

Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0508700);

National Natural Science Foundation of China (82370577);

National Natural Science Foundation of China (82070588);

National Natural Science Foundation of China (82000690)

More Information

Corresponding author: ZHENG Minghua， zhengmh@wmu.edu.cn （ORCID： 0000-0003-4984-2631）
Received Date: 2025-06-12
Accepted Date: 2025-07-08
Published Date: 2025-09-25

Abstract

Abstract

This article investigates the collaborative management of metabolic dysfunction-associated fatty liver disease （MAFLD） and chronic kidney disease （CKD）. As major public health issues worldwide， MAFLD and CKD are closely related in terms of epidemiology， pathogenesis， and management strategies， and however， there are still many challenges in the multidisciplinary collaborative management of the two diseases. This article systematically elaborates on the epidemiology of MAFLD and CKD， summarizes their common risk factors such as metabolic disorder， genetic susceptibility， and active metabolites， and reviews the mutual screening strategies and combined management models based on noninvasive imaging， serum markers， FIB-4 score， and liver stiffness measurement. In addition， this article summarizes the advances in the application of lifestyle intervention and new drugs （such as GLP-1 receptor agonists and SGLT-2 inhibitors） and emphasizes the importance of multidisciplinary collaboration in improving the prognosis of patients. Due to the close association between MAFLD and CKD， their joint management is crucial， and therefore， it is necessary to establish a multidisciplinary collaboration mechanism and implement the measures of precise screening， comprehensive treatment， and long-term monitoring， so as to improve the prognosis of patients and reduce the risk of complications. Finally， this article proposes that in the future， more effective combined treatment regimens should be explored to expand the clinical options for the co-management of the liver and the kidney.
- Metabolic Dysfunction-associated Fatty Liver Disease,
- Kidney Diseases,
- Disease Management

FullText(HTML)

References(77)

References

[1]	MIAO L, TARGHER G, BYRNE CD, et al. Current status and future trends of the global burden of MASLD[J]. Trends Endocrinol Metab, 2024, 35( 8): 697- 707. DOI: 10.1016/j.tem.2024.02.007.
[2]	HO GJK, TAN FXN, SASIKUMAR NA, et al. High global prevalence of steatotic liver disease and associated subtypes: A meta-analysis[J]. Clin Gastroenterol Hepatol, 2025. DOI: 10.1016/j.cgh.2025.02.006.[ Epub ahead of print].
[3]	LOU TW, YANG RX, FAN JG. The global burden of fatty liver disease: The major impact of China[J]. Hepatobiliary Surg Nutr, 2024, 13( 1): 119- 123. DOI: 10.21037/hbsn-23-556.
[4]	LE MH, LE DM, BAEZ TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1, 201, 807 persons[J]. J Hepatol, 2023, 79( 2): 287- 295. DOI: 10.1016/j.jhep.2023.03.040.
[5]	RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77( 5): 1797- 1835. DOI: 10.1097/HEP.0000000000000323.
[6]	MURRAY CJL, 2021 COLLABORATORS GBD. Findings from the global burden of disease study 2021[J]. Lancet, 2024, 403( 10440): 2259- 2262. DOI: 10.1016/S0140-6736(24)00769-4.
[7]	Disease Kidney: Improving Global Outcomes CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int, 2024, 105( 4S): S117- S314. DOI: 10.1016/j.kint.2023.10.018.
[8]	GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395( 10225): 709- 733. DOI: 10.1016/S0140-6736(20)30045-3.
[9]	DUELL PB, WELTY FK, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American heart association[J]. Arterioscler Thromb Vasc Biol, 2022, 42( 6): e168- e185. DOI: 10.1161/ATV.0000000000000153.
[10]	SUN DQ, TARGHER G, BYRNE CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease[J]. Hepatobiliary Surg Nutr, 2023, 12( 3): 386- 403. DOI: 10.21037/hbsn-22-421.
[11]	MUSSO G, GAMBINO R, TABIBIAN JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis[J]. PLoS Med, 2014, 11( 7): e1001680. DOI: 10.1371/journal.pmed.1001680.
[12]	SUN DQ, JIN Y, WANG TY, et al. MAFLD and risk of CKD[J]. Metabolism, 2021, 115: 154433. DOI: 10.1016/j.metabol.2020.154433.
[13]	RODERBURG C, KRIEG S, KRIEG A, et al. Non-alcoholic fatty liver disease(NAFLD) is associated with an increased incidence of chronic kidney disease(CKD)[J]. Eur J Med Res, 2023, 28( 1): 153. DOI: 10.1186/s40001-023-01114-6.
[14]	SUN DQ, SHEN JQ, TONG XF, et al. Liver fibrosis progression analyzed with AI predicts renal decline[J]. JHEP Rep, 2025, 7( 5): 101358. DOI: 10.1016/j.jhepr.2025.101358.
[15]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
[16]	LIU HX, ZHANG C, XIONG J. Pathological connections between nonalcoholic fatty liver disease and chronic kidney disease[J]. Kidney Dis(Basel), 2022, 8( 6): 458- 465. DOI: 10.1159/000527834.
[17]	MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals[J]. Gut, 2021, 70( 5): 962- 969. DOI: 10.1136/gutjnl-2020-322572.
[18]	POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics[J]. Metabolism, 2019, 92: 82- 97. DOI: 10.1016/j.metabol.2018.11.014.
[19]	BILSON J, HYDES TJ, MCDONNELL D, et al. Impact of metabolic syndrome traits on kidney disease risk in individuals with MASLD: A UK biobank study[J]. Liver Int, 2025, 45( 4): e16159. DOI: 10.1111/liv.16159.
[20]	BYRNE CD, TARGHER G. NAFLD as a driver of chronic kidney disease[J]. J Hepatol, 2020, 72( 4): 785- 801. DOI: 10.1016/j.jhep.2020.01.013.
[21]	SUN DQ, ZHENG KI, XU G, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels[J]. Liver Int, 2020, 40( 1): 107- 119. DOI: 10.1111/liv.14251.
[22]	TARGHER G, MANTOVANI A, ALISI A, et al. Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD[J]. Hepatology, 2019, 70( 1): 142- 153. DOI: 10.1002/hep.30625.
[23]	XU RF, TAO AY, ZHANG SS, et al. Association between patatin-like phospholipase domain containing 3 gene(PNPLA3) polymorphisms and nonalcoholic fatty liver disease: A HuGE review and meta-analysis[J]. Sci Rep, 2015, 5: 9284. DOI: 10.1038/srep09284.
[24]	WANG TY, WANG RF, BU ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease[J]. Nat Rev Nephrol, 2022, 18( 4): 259- 268. DOI: 10.1038/s41581-021-00519-y.
[25]	ONIKI K, SARUWATARI J, IZUKA T, et al. Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects[J]. PLoS One, 2015, 10( 7): e0132640. DOI: 10.1371/journal.pone.0132640.
[26]	MANTOVANI A, ZUSI C, SANI E, et al. Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease[J]. Diabetes Metab, 2019, 45( 5): 480- 487. DOI: 10.1016/j.diabet.2019.01.011.
[27]	MARZUILLO P, DI SESSA A, GUARINO S, et al. Non-alcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity[J]. Pediatr Obes, 2019, 14( 10): e12539. DOI: 10.1111/ijpo.12539.
[28]	LUUKKONEN PK, TUKIAINEN T, JUUTI A, et al. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in non-alcoholic fatty liver disease[J]. JCI Insight, 2020, 5( 5): e132158. DOI: 10.1172/jci.insight.132158.
[29]	di SESSA A, UMANO GR, CIRILLO G, et al. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant[J]. World J Gastroenterol, 2020, 26( 36): 5474- 5483. DOI: 10.3748/wjg.v26.i36.5474.
[30]	SUN DQ, WANG TY, ZHENG KI, et al. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven non-alcoholic fatty liver disease[J]. Nutr Metab Cardiovasc Dis, 2021, 31( 6): 1822- 1831. DOI: 10.1016/j.numecd.2021.02.018.
[31]	RAJ D, TOMAR B, LAHIRI A, et al. The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease[J]. Pharmacol Res, 2020, 152: 104617. DOI: 10.1016/j.phrs.2019.104617.
[32]	MEIJERS B, EVENEPOEL P, ANDERS HJ. Intestinal microbiome and fitness in kidney disease[J]. Nat Rev Nephrol, 2019, 15( 9): 531- 545. DOI: 10.1038/s41581-019-0172-1.
[33]	LARABI AB, MASSON HLP, BÄUMLER AJ. Bile acids as modulators of gut microbiota composition and function[J]. Gut Microbes, 2023, 15( 1): 2172671. DOI: 10.1080/19490976.2023.2172671.
[34]	WU HY, CHEN JJ, GUO SY, et al. Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease[J]. Gut Microbes, 2025, 17( 1): 2500099. DOI: 10.1080/19490976.2025.2500099.
[35]	CHEN WY, ZHANG JH, CHEN LL, et al. Bioactive metabolites: A clue to the link between MASLD and CKD?[J]. Clin Mol Hepatol, 2025, 31( 1): 56- 73. DOI: 10.3350/cmh.2024.0782.
[36]	CHEN F, ESMAILI S, ROGERS GB, et al. Lean NAFLD: A distinct entity shaped by differential metabolic adaptation[J]. Hepatology, 2020, 71( 4): 1213- 1227. DOI: 10.1002/hep.30908.
[37]	ADORINI L, TRAUNER M. FXR agonists in NASH treatment[J]. J Hepatol, 2023, 79( 5): 1317- 1331. DOI: 10.1016/j.jhep.2023.07.034.
[38]	HERMAN-EDELSTEIN M, WEINSTEIN T, LEVI M. Bile acid receptors and the kidney[J]. Curr Opin Nephrol Hypertens, 2018, 27( 1): 56- 62. DOI: 10.1097/MNH.0000000000000374.
[39]	BILSON J, MANTOVANI A, BYRNE CD, et al. Steatotic liver disease, MASLD and risk of chronic kidney disease[J]. Diabetes Metab, 2024, 50( 1): 101506. DOI: 10.1016/j.diabet.2023.101506.
[40]	CHEN LD, HUANG JF, CHEN QS, et al. Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome[J]. Chin Med J(Engl), 2019, 132( 22): 2670- 2676. DOI: 10.1097/CM9.0000000000000503.
[41]	HUI M, LI YH, YE JY, et al. Obstructive sleep apnea-hypopnea syndrome(OSAHS) comorbid with diabetes rather than OSAHS alone serves an independent risk factor for chronic kidney disease(CKD)[J]. Ann Palliat Med, 2020, 9( 3): 858- 869. DOI: 10.21037/apm.2020.03.21.
[42]	HYDES T, BROWN E, HAMID A, et al. Current and emerging biomarkers and imaging modalities for non-alcoholic fatty liver disease: Clinical and research applications[J]. Clin Ther, 2021, 43( 9): 1505- 1522. DOI: 10.1016/j.clinthera.2021.07.012.
[43]	Chinese Society of Hepatology, Chinese Medical Association[J]. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(Version 2024)[ J]. J Prac Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163. 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
[44]	NAKATSUKA T, TATEISHI R, SATO M, et al. Agile scores are a good predictor of liver-related events in patients with NAFLD[J]. J Hepatol, 2023, 79( 3): e126- e127. DOI: 10.1016/j.jhep.2023.02.029.
[45]	NEWSOME PN, SASSO M, DEEKS JJ, et al. FibroScan-AST(FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5( 4): 362- 373. DOI: 10.1016/S2468-1253(19)30383-8.
[46]	YANG TY, YANG BQ, YIN JY, et al. Targeting insulin resistance and liver fibrosis: CKD screening priorities in MASLD[J]. Biomedicines, 2025, 13( 4): 842. DOI: 10.3390/biomedicines13040842.
[47]	CHEN DC, SHLIPAK MG, SCHERZER R, et al. Association of intraindividual difference in estimated glomerular filtration rate by creatinine vs cystatin C and end-stage kidney disease and mortality[J]. JAMA Netw Open, 2022, 5( 2): e2148940. DOI: 10.1001/jamanetworkopen.2021.48940.
[48]	TIAN T, ZENG J, LI YC, et al. Joint effects of sleep disturbance and renal function impairment on incident new-onset severe metabolic dysfunction-associated steatotic liver disease[J]. Diabetes Obes Metab, 2024, 26( 10): 4724- 4733. DOI: 10.1111/dom.15841.
[49]	INKER LA, SCHMID CH, TIGHIOUART H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C[J]. N Engl J Med, 2012, 367( 1): 20- 29. DOI: 10.1056/NEJMoa1114248.
[50]	Chapter 2: Definition, identification, and prediction of CKD progression[J]. Kidney Int Suppl(2011), 2013, 3( 1): 63- 72. DOI: 10.1038/kisup.2012.65.
[51]	INKER LA, GRAMS ME, LEVEY AS, et al. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: An individual participant data meta-analysis in a global consortium[J]. Am J Kidney Dis, 2019, 73( 2): 206- 217. DOI: 10.1053/j.ajkd.2018.08.013.
[52]	LEVEY AS, GANSEVOORT RT, CORESH J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European medicines agency[J]. Am J Kidney Dis, 2020, 75( 1): 84- 104. DOI: 10.1053/j.ajkd.2019.06.009.
[53]	MADERO M, LEVIN A, AHMED SB, et al. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2024 clinical practice guideline[J]. Ann Intern Med, 2025, 178( 5): 705- 713. DOI: 10.7326/annals-24-01926.
[54]	Chinese Society of Endocrinology, China Endocrinology and Metabolism Specialist Alliance. Expert consensus on clinical management for chronic kidney disease in diabetes mellitus in China[J]. Chin J Endocrinol Metab, 2024, 40( 6): 455- 461. DOI: 10.3760/cma.j.cn311282-20240509-00187. 中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 中国糖尿病合并慢性肾脏病临床管理共识[J]. 中华内分泌代谢杂志, 2024, 40( 6): 455- 461. DOI: 10.3760/cma.j.cn311282-20240509-00187.
[55]	KIAPIDOU S, LIAVA C, KALOGIROU M, et al. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know?[J]. Ann Hepatol, 2020, 19( 2): 134- 144. DOI: 10.1016/j.aohep.2019.07.013.
[56]	ALBERT SG, WOOD EM. FIB-4 as a screening and disease monitoring method in pre- fibrotic stages of metabolic dysfunction-associated fatty liver disease(MASLD)[J]. J Diabetes Complications, 2024, 38( 7): 108777. DOI: 10.1016/j.jdiacomp.2024.108777.
[57]	DONG BQ, ZHAO YT, WANG JL, et al. Epidemiological analysis of chronic kidney disease from 1990 to 2019 and predictions to 2030 by Bayesian age-period-cohort analysis[J]. Ren Fail, 2024, 46( 2): 2403645. DOI: 10.1080/0886022X.2024.2403645.
[58]	CHEN F, WANG M, JIANG Y. Prevalence of chronic kidney disease and metabolic related indicators in Mianzhu, Sichuan, China[J]. Front Public Health, 2024, 11: 1252110. DOI: 10.3389/fpubh.2023.1252110.
[59]	BOECKMANS J, HAGSTRÖM H, CRYER DR, et al. The importance of patient engagement in the multimodal treatment of MASLD[J]. Commun Med(Lond), 2025, 5( 1): 148. DOI: 10.1038/s43856-025-00871-1.
[60]	ELSAYED NA, ALEPPO G, ARODA VR, et al. 10. cardiovascular disease and risk management: Standards of care in diabetes-2023[J]. Diabetes Care, 2023, 46( S1): S158- S190. DOI: 10.2337/dc23-s010.
[61]	CHANG PY, CHIEN LN, LIN YF, et al. Simultaneous control of glycemic, blood pressure, and lipid significantly reduce the risk of renal progression in diabetes patients[J]. Eur J Intern Med, 2016, 36: 87- 92. DOI: 10.1016/j.ejim.2016.09.013.
[62]	HAIGH L, KIRK C, GENDY K EL, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease(NAFLD): A systematic review and meta-analysis[J]. Clin Nutr, 2022, 41( 9): 1913- 1931. DOI: 10.1016/j.clnu.2022.06.037.
[63]	HADEFI A, ARVANITAKIS M, TRÉPO E, et al. Dietary strategies in non-alcoholic fatty liver disease patients: From evidence to daily clinical practice, a systematic review[J]. United European Gastroenterol J, 2023, 11( 7): 663- 689. DOI: 10.1002/ueg2.12443.
[64]	SIMANCAS-RACINES D, ANNUNZIATA G, VERDE L, et al. Nutritional strategies for battling obesity-linked liver disease: The role of medical nutritional therapy in metabolic dysfunction-associated steatotic liver disease(MASLD) management[J]. Curr Obes Rep, 2025, 14( 1): 7. DOI: 10.1007/s13679-024-00597-6.
[65]	GHAFFARI M, SADEGHIYAN S, FARAMARZI M, et al. The effect of aerobic exercise on metabolic parameters of patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis[J]. J Sports Med Phys Fitness, 2023, 63( 1): 178- 187. DOI: 10.23736/S0022-4707.22.13801-6.
[66]	ZHANG XL, GU YQ, ZHAO J, et al. Associations between skeletal muscle strength and chronic kidney disease in patients with MASLD[J]. Commun Med(Lond), 2025, 5( 1): 118. DOI: 10.1038/s43856-025-00821-x.
[67]	PALMER SC, TENDAL B, MUSTAFA RA, et al. Sodium-glucose cotransporter protein-2(SGLT-2) inhibitors and glucagon-like peptide-1(GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials[J]. BMJ, 2021, 372: m4573. DOI: 10.1136/bmj.m4573.
[68]	LI DD, SHI WL, WANG TS, et al. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis[J]. Diabetes Obes Metab, 2018, 20( 8): 1972- 1976. DOI: 10.1111/dom.13294.
[69]	COLHOUN HM, LINGVAY I, BROWN PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial[J]. Nat Med, 2024, 30( 7): 2058- 2066. DOI: 10.1038/s41591-024-03015-5.
[70]	NEWSOME PN, SANYAL AJ, ENGEBRETSEN KA, et al. Semaglutide 2.4 Mg in participants with metabolic dysfunction-associated steatohepatitis: Baseline characteristics and design of the phase 3 ESSENCE trial[J]. Aliment Pharmacol Ther, 2024, 60( 11-12): 1525- 1533. DOI: 10.1111/apt.18331.
[71]	ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387( 10019): 679- 690. DOI: 10.1016/S0140-6736(15)00803-X.
[72]	MANN JFE, ØRSTED DD, BROWN-FRANDSEN K, et al. Liraglutide and renal outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377( 9): 839- 848. DOI: 10.1056/nejmoa1616011.
[73]	PERKOVIC V, TUTTLE KR, ROSSING P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J]. N Engl J Med, 2024, 391( 2): 109- 121. DOI: 10.1056/NEJMoa2403347.
[74]	MA J, HU XY, ZHANG WC, et al. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice[J]. Endocrine, 2025, 87( 1): 159- 169. DOI: 10.1007/s12020-024-03998-8.
[75]	SANYAL AJ, KAPLAN LM, FRIAS JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial[J]. Nat Med, 2024, 30( 7): 2037- 2048. DOI: 10.1038/s41591-024-03018-2.
[76]	ZHOU D, FAN JG. Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction[J]. Chin Med J(Engl), 2024, 137( 22): 2687- 2696. DOI: 10.1097/CM9.0000000000003355.
[77]	RAMOS AM, FERNÁNDEZ-FERNÁNDEZ B, PÉREZ-GÓMEZ MV, et al. Design and optimization strategies for the development of new drugs that treat chronic kidney disease[J]. Expert Opin Drug Discov, 2020, 15( 1): 101- 115. DOI: 10.1080/17460441.2020.1690450.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (176) PDF downloads(62)

Co-management of the liver and the kidney： New prospects in the clinical management of metabolic dysfunction-associated fatty liver disease with chronic kidney disease

DOI: 10.12449/JCH250905

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Co-management of the liver and the kidney： New prospects in the clinical management of metabolic dysfunction-associated fatty liver disease with chronic kidney disease

DOI: 10.12449/JCH250905

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content